BRINAVESS

This brand name is authorized in Austria, Canada, Croatia, Cyprus, Estonia, Finland, Hong Kong SAR China, Ireland, Israel, Lithuania, Netherlands, Poland, Romania, South Africa, Spain, UK.

Active ingredients

The drug BRINAVESS contains one active pharmaceutical ingredient (API):

1	Vernakalant UNII 7G4J1ZD9UQ - VERNAKALANT HYDROCHLORIDE
	Vernakalant is an antiarrhythmic medicine that acts preferentially in the atria to prolong atrial refractoriness and to rate-dependently slow impulse conduction.
	Read more about Vernakalant

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
BRIVANESS Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C01BG11	Vernakalant	C Cardiovascular system → C01 Cardiac therapy → C01B Antiarrhythmics, class I and III → C01BG Other class I antiarrhythmics
Discover more medicines within C01BG11

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02462400
EE	Ravimiamet	1493423, 1493434
ES	Centro de información online de medicamentos de la AEMPS	10645002
FI	Lääkealan turvallisuus- ja kehittämiskeskus	411305
GB	Medicines & Healthcare Products Regulatory Agency	372350
HK	Department of Health Drug Office	61191
IL	מִשְׂרַד הַבְּרִיאוּת	8360, 8976
LT	Valstybinė vaistų kontrolės tarnyba	1056397, 1056398
NL	Z-Index G-Standaard, PRK	97640
PL	Rejestru Produktów Leczniczych	100236700
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W60089001, W60089002
ZA	Health Products Regulatory Authority	45/6.2/0350, 45/6.2/0351